01—Abstract
Summary
Summary of the 8-K filed February 10, 2025. Cited figures are marked; the original filing is the authoritative source.
Roivant Sciences Ltd. (Nasdaq: ROIV) furnished a press release under Item 2.02 reporting financial results for the fiscal third quarter ended December 31, 2024, and providing a business update.
The company reported consolidated cash, cash equivalents, restricted cash and marketable securities of approximately $5.2 billiona at December 31, 2024. Net loss from continuing operations was $208.9 million for the quarter, compared with income from continuing operations of $5.1 billion a year earlier, which included a gain on the Telavant sale. Quarterly income from discontinued operations of $327.0 million reflected the gain on the sale of the entire equity interest in Dermavant to Organon in October 2024.
Operating expenses rose year over year. R&D expenses increased to $141.6 millionb from $108.1 million, driven mainly by anti-FcRn franchise program costs, and G&A expenses increased to $141.5 million from $128.2 million, largely due to share-based compensation tied to July 2024 long-term equity awards. Revenue, net was $9.0 million for the quarter versus $15.6 million a year earlier.
The update centers on pipeline milestones. Immunovant expects topline batoclimab results in myasthenia gravis and initial CIDP period 1 results by March 31, 2025, and initiated pivotal IMVT-1402 studies in Graves' disease and difficult-to-treat rheumatoid arthritis. Priovant added cutaneous sarcoidosis as a third brepocitinib indication, with a Phase 2 start expected in Q2 calendar 2025.
Kinevant discontinued namilumab for sarcoidosis after a Phase 2 study failed to show treatment benefit. The Genevant litigation against Moderna continues, with a jury trial scheduled for September 2025.
02—Key points
Key Highlights
- Consolidated cash, cash equivalents, restricted cash and marketable securities of approximately $5.2 billion at December 31, 2024, excluding a $75 million regulatory milestone received in January 2025 and $113 million of external capital raised in Immunovant's January private placement.
- Net loss from continuing operations of $208.9 million for the quarter, or $0.22 per share, versus income from continuing operations of $5.1 billion in the prior-year quarter, which included the Telavant sale gain.
- Income from discontinued operations of $327.0 million, reflecting the gain on the sale of Roivant's entire equity interest in Dermavant to Organon in October 2024.
- R&D expenses rose to $141.6 million from $108.1 million, driven by a $29.1 million increase in anti-FcRn franchise expense; G&A rose to $141.5 million from $128.2 million on higher share-based compensation.
- Immunovant's January 2025 private placement of $450 million raised Roivant's basic ownership to approximately 57%.
- Batoclimab pivotal myasthenia gravis topline results and initial CIDP period 1 results are expected by March 31, 2025.
- Kinevant discontinued namilumab for sarcoidosis after a Phase 2 study failed to show treatment benefit; Priovant added cutaneous sarcoidosis as a third brepocitinib indication, with topline results expected in the second half of calendar 2026.
03—Questions
Frequently Asked Questions
How much cash did Roivant have at the end of the quarter?
Roivant reported consolidated cash, cash equivalents, restricted cash and marketable securities of approximately $5.2 billion at December 31, 2024. This figure excludes a one-time $75 million regulatory milestone received in January 2025 for VTAMA approval in atopic dermatitis and $113 million of external capital raised in Immunovant's January private placement.
Why did the company report a loss from continuing operations this quarter compared with a large income a year earlier?
The prior-year quarter included a $5.3 billion gain on the sale of Telavant net assets to Roche in December 2023. This quarter, the company reported a loss from continuing operations of $208.9 million, driven by higher R&D and G&A expenses and a $274.4 million operating loss, partly offset by $61.9 million of interest income.
What drove the $327.0 million of income from discontinued operations?
The income reflects the gain on the sale of Roivant's entire equity interest in its majority-owned subsidiary Dermavant to Organon in October 2024, partially offset by Dermavant's net losses.
What are the key upcoming catalysts for investors?
The filing lists batoclimab topline results in myasthenia gravis and initial CIDP period 1 results by March 31, 2025, batoclimab thyroid eye disease topline results in the second half of calendar 2025, brepocitinib dermatomyositis Phase 3 topline results in the second half of calendar 2025, and a Moderna jury trial in the Genevant LNP litigation scheduled for September 2025.
Why did G&A expenses increase this quarter?
G&A expenses increased by $13.4 million to $141.5 million, largely due to a $25.0 million increase in share-based compensation from long-term equity incentive awards granted in July 2024. This was partially offset by a $15.9 million decrease in personnel-related expenses, which were higher in the prior-year quarter due to a one-time cash retention bonus.
04—Continue